General Information of Drug (ID: DM1YSMD)

Drug Name
MEDI6383 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM1YSMD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [3]
RG7888 DM2SWI8 Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Amlitelimab DMKR3BQ Asthma CA23 Phase 2 [5]
mRNA-2752 DMUKBI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
mRNA-2416 DMFTAWU Lymphoma 2A80-2A86 Phase 1 [7]
SAR442970 DM3DHWE Inflammation 1A00-CA43.1 Phase 1 [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TAX transcriptionally-activated glycoprotein 1 (OX40) TTBW580 TNFL4_HUMAN Not Available [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041453)
2 J Clin Oncol 33, 2015 (suppl; abstr 3056).
3 Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
4 Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
5 OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
6 Clinical pipeline report, company report or official report of Moderna Therapeutics.
7 Clinical pipeline report, company report or official report of Moderna Therapeutics.
8 Clinical pipeline report, company report or official report of Sanofi